Comparison of ofatumumab and other disease-modifying therapies for relapsing multiple sclerosis: a network meta-analysis-Reference-Cited by-同舟云学术

Comparison of ofatumumab and other disease-modifying therapies for relapsing multiple sclerosis: a network meta-analysis

Published:2020-12 Issue:18 Volume:9 Page:1255-1274
ISSN:2042-6305
Container-title:Journal of Comparative Effectiveness Research
language:en
Short-container-title:Journal of Comparative Effectiveness Research

Author:

Samjoo Imtiaz A¹^ORCID,Worthington Evelyn¹^ORCID,Drudge Christopher¹^ORCID,Zhao Melody¹^ORCID,Cameron Chris²^ORCID,Häring Dieter A³,Stoneman Dee³,Klotz Luisa⁴,Adlard Nicholas³^ORCID

Affiliation:

1. EVERSANA™, 204-3228 South Service Road, Burlington, Ontario L7N 3H8, Canada

2. EVERSANA™, 207-275 Charlotte Street, Sydney, Nova Scotia B1P 1C6, Canada

3. Novartis Pharma AG, Fabrikstrasse 12, 4002 Basel, Switzerland

4. Department of Neurology, University Hospital Münster, Westfälische-Wilhelms-University Münster, Münster, Germany

Abstract

Aim: To compare the efficacy of ofatumumab to other disease-modifying therapies (DMTs) for relapsing multiple sclerosis (RMS). Materials & methods: A network meta-analysis was conducted to determine the relative effect of ofatumumab on annualized relapse rate and confirmed disability progression at 3 months and 6 months. Results: For each outcome, ofatumumab was as effective as other highly efficacious monoclonal antibody DMTs (i.e., alemtuzumab, natalizumab and ocrelizumab). Conclusion: Ofatumumab offers beneficial outcomes for RMS by reducing relapse and disability progression risk.

Publisher

Future Medicine Ltd

Subject

Health Policy

Link

https://www.futuremedicine.com/doi/pdf/10.2217/cer-2020-0122

Reference50 articles.

1. National Multiple Sclerosis Society. Definition of MS (2020). http://www.nationalmssociety.org/What-is-MS/Definition-of-MS

2. Defining the clinical course of multiple sclerosis: The 2013 revisions

3. Natural history of secondary-progressive multiple sclerosis

4. Onset of secondary progressive phase and long-term evolution of multiple sclerosis

5. Association of British Neurologists: revised (2015) guidelines for prescribing disease-modifying treatments in multiple sclerosis

Cited by 47 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. ENTIMOS: Decision Support Tool Highlights Potential Impact of Non-intravenous Therapies for Multiple Sclerosis on Patient Care via Clinical Scenario Simulation;PharmacoEconomics - Open;2024-07-11

2. Ocrelizumab and ofatumumab comparison: an Italian real-world propensity score matched study;Journal of Neurology;2024-05-04

3. Ofatumumab in clinical practice;Neurologie pro praxi;2024-03-06

4. Ofatumumab: A Novel Anti-CD20 Monoclonal Antibody for Multiple Sclerosis: A Review of Clinical Considerations;SN Comprehensive Clinical Medicine;2024-02-08

5. Comparative efficacy of ofatumumab versus oral therapies for relapsing multiple sclerosis patients using propensity score analyses and simulated treatment comparisons;Therapeutic Advances in Neurological Disorders;2024-01